Acepodia Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy Posted on 2024-02-042024-03-13 by maxproadmin More >>
Acepodia Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies Posted on 2021-12-022022-09-15 by maxproadmin More >>
Acepodia Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments Posted on 2021-11-032021-12-09 by maxproadmin More >>
Acepodia Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors Posted on 2021-09-162021-11-03 by maxproadmin More >>
Acepodia Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress Posted on 2021-09-132021-11-03 by maxproadmin More >>
Acepodia Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers Posted on 2021-06-072021-07-26 by maxproadmin More >>
Acepodia The Return of Jimmy Lai | Jimmy Lai, CFO, Acepodia Posted on 2021-05-192021-06-03 by maxproadmin More >>
Acepodia Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers Posted on 2021-05-192021-06-03 by maxproadmin More >>
Acepodia Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer Posted on 2021-05-112021-06-03 by maxproadmin More >>
Acepodia Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells Posted on 2021-03-162021-05-27 by maxproadmin More >>
